Plunkett Research Online: Novo Nordisk AS

NOVO NORDISK AS (NVO:NYS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, or.....



Novo Nordisk AS
Ticker: NVO
Exchange: NYS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 45 44448888
Fax: 45 44490555
Address: Novo Alle 1
Bagsvaerd, 2880 Denmark

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Drugs-Diabetes and Obesity
Pharmaceuticals
Drug Research and Development
Insulin
Diabetes
Obesity
Fertility
Hemophilia
Contacts Description
Lars JorgensenCEO/President
Karsten KnudsenCFO/Executive VP
See More
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, or.....See More See More

Auditor: Deloitte Statsautoriseret Revisionspartnerselskab
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Ozempic
Wegovy
NovoFine
Tresiba
Saxenda
NovoSeven
Norditropin
Emisphere Technologies Inc
NameTitleSalary (DKK)Bonus (DKK)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors:

About 28% of the firm's outstanding stock (and 75% of the vote) are held by the Novo Nordisk Foundation, one of the world's largest charitable foundations.